| Year | Journal or Conference | Title | |
|---|---|---|---|
| 2025 | Oncoimmunology | CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies |  |
| 2025 | ASH | MULTI-OMICS INTEGRATION REVEALS THERAPEUTIC VULNERABILITIES AND IMMUNE MICROENVIRONMENT SUBTYPES IN ACUTE MYELOID LEUKEMIA | |
| 2025 | ASH | Phenotype and functional state of endogenous T-cells support T-cell engager therapy in the post-CAR T therapy setting | |
| 2024 | Blood | Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation | |
| 2024 | JOBIM | DiagBIOsis : A bioinformatic tool for high-throughput data analysis and visualization | |
| 2024 | EHA | Deciphering Multiple Myeloma Complexity : Exploring Tumor Microenvironment Dynamics Through Multi-Omics integration for Personalized Therapeutic Insights | |
| 2024 | EHA | Implication of glycolytic and mitochondrial metabolism in Multiple Myeloma response to anti-CD38 Daratumumab treatment | |
| 2024 | EHA | CD200 IMMUNE CHECKPOINT EXPRESSION IS ASSOCIATED WITH TREATMENT RESISTANCE AND INFERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS TREATED BY ANTI-CD38 MoAb | |
| 2023 | Frontiers in Oncology | Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma | |
| 2023 | Leukemia | EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma | |
| 2023 | ASH | Integrative Multiomics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications | |
| 2023 | ASH | Characterization of a new metabolic score correlated with the CD38 cell-surface expression and response to daratumumab treatment in multiple myeloma | |
| 2022 | Theranostics | Comprehensive Characterization of the Epigenetic Landscape in Multiple Myeloma | |
| 2022 | EHA | Characterization of Multiple Myeloma cell lines with Acquired-Resistance to Proteasome Inhibitors highlights a link between resistance and metabolic deregulation. | |
| 2022 | EHA | METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINES TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS | |
| 2022 | AFC | CELL-SURFACE CD38 EXPRESSION IN RESPONSE TO EZH2I AS THERAPEUTIC STRATEGY FOR ANTI-CD38 ANTIBODIES TREATMENT IN MULTIPLE MYELOMA | |
| 2022 | ASH | EZH2 TARGETING INDUCES CD38 UPREGULATION AND RESPONSE TO ANTI-CD38 ANTIBODIES IN MULTIPLE MYELOMA | |
| 2022 | ASH | DEVELOPMENT OF A ROBUST BH3 PROFILING TOOLKIT FOR PRECISION MEDICINE IN HEMATOLOGIC MALIGNANCIES | |
| 2022 | Frontiers in Immunology | The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance | |
| 2021 | Personalized Medecine | RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma | |
| 2017 | ASH | Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma | |
